-
Patent Agency Ranking
公开(公告)号：US20210163601A1
公开(公告)日：2021-06-03
申请号：US16987237
申请日：2020-08-06
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , A61P9/10 , A61P9/04 , C12N15/113 , C07H21/02 , A61P3/06 , A61K39/395 , A61K45/06
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US20190248902A1
公开(公告)日：2019-08-15
申请号：US16230356
申请日：2018-12-21
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , C07H21/02 , A61K39/395 , A61P9/10 , A61P9/04 , A61K45/06 , C12N15/113
CPC classification number: C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US20250051457A1
公开(公告)日：2025-02-13
申请号：US18770259
申请日：2024-07-11
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mingtung Chan
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P3/06 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C12N15/113
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
公开(公告)号：US11926672B2
公开(公告)日：2024-03-12
申请号：US17127629
申请日：2020-12-18
Applicant: Amgen Inc.
Inventor： Xin Yu , Jackson Egen , Fernando Garces , Shunsuke Takenaka , AeRyon Kim , Deepali Sawant
CPC classification number: C07K16/2878 , A61P35/04 , C07K16/30 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/75 , C07K2317/92
Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
-
公开(公告)号：US20170088620A1
公开(公告)日：2017-03-30
申请号：US15279162
申请日：2016-09-28
Applicant: Amgen Inc.
Inventor： Paul Nioi , Peter Coward , Christopher Murawsky , Derek E. Piper , Fernando Garces , Jun Zhang , Yang Li , Brian Mintung Chang
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2851 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61P9/04 , A61P9/10 , C07H21/02 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N15/1138
Abstract: Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.
-
-
-
-
Search Results
5
records
(took 0.051 seconds)
